I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

Nuvation Bio is downgraded from Buy to Hold as its stock price now reflects improved Ibtrozi rollout visibility and strong fundamentals. Ibtrozi's commercial launch is robust, with early patient ...

G2 Bio Companies has launched with $200 million in financing from Temasek to develop gene therapy candidates out of the University of Pennsylvania. The company is led by Penn gene therapy expert James ...

Seers Technology, D&D Pharmatech, OliX, ABL Bio. Among the top 10 stocks by share price growth this year, four were bio·healthcare-related. Seers Technology, an AI medical device company, saw its ...

While some synthetic biology companies are using biology to improve our food, clothes, and medicine, others are turning their attention to helping the Earth. On GEN Live, we’ll talk to Syn Bio ...